The TOPVAS study addresses the limitations of current prognostic tools, as many kidney allografts are still lost annually due to complications. It uses state-of-the-art bioinformatic and systems biology tools to analyze genetic data from 72 pre-implantation biopsies. The research has identified promising predictive markers, such as CDKN2A, whose values combined with donor age offered the best prediction for one-year serum creatinine levels. An innovative cell viability staining technology known as "BIOPSYCHRONOLOGY" is also being employed. The study's primary outcome measure is to ultimately validate the prognostic information on long-term transplant outcomes in an independent patient population.
Topvas is built on a simple philosophy: Simplicity is the ultimate sophistication. We realized that users don't need more buttons; they need better results. With a clean interface and lightning-fast response times, Topvas turns your "To-Do" list into a "Done" list before your coffee gets cold.
Fluctuations in overall kidney function variables like serum urea and the urine protein-to-creatinine ratio. Key Findings and Clinical Outcomes topvas
are appropriate for sales, focusing on building trust rather than sounding like a typical salesperson. 4. Compensation and Expectations
Incomplete understanding of graft failure causes and a lack of reliable prognostic tools. The TOPVAS study addresses the limitations of current
Recruitment of 241 deceased-donor kidney transplant recipients across centers in Innsbruck, Linz, and Vienna.
: Providing high-level business support, including project management, operations, and administrative delegation. An innovative cell viability staining technology known as
Longitudinal tracking of clinical data, blood, and urine samples at baseline, 3, 12, and 24 months. 3. Results Survival Rates: Report on graft and patient survival (e.g., patient survival at 24 months).